Biocept further expands its patent estate for capturing and detecting target cells of interest, including circulating tumor cells SAN DIEGO , Jan. 8, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular offerings designed to provide physicians with
SAN DIEGO , May 7, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular diagnostics company specializing in oncology biomarker detection and monitoring through circulating tumor cells (CTCs) and cell-free circulating tumor DNA, today announced that it has closed a loan facility of up
Biocept, Inc. Pioneers Revolutionary Diagnostics Aimed at Personalized Cancer Management We noted earlier this week that San Diego?based Biocept, which is developing advanced cancer diagnostics technology, had recently raised $2.3 million from its investors.
SAN DIEGO , Feb. 9, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA and circulating tumor cells, today announced the pricing of an underwritten public offering of 8,000,000 shares of its
SAN DIEGO , May 4, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and Circulating Tumor Cells (CTCs), today announced that the Company will issue its financial results for the first
SAN DIEGO , Feb. 25, 2015 (GLOBE NEWSWIRE) -- Biocept , Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), today announced that the Company will issue its financial results for the
SAN DIEGO, Nov. 6, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (cfDNA) and circulating tumor cells (CTCs), today announced that the Company will issue its financial results for
SAN DIEGO, March 5, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), an oncology diagnostics company focused on improving individual patient treatment, announced today that the Company's President and Chief Executive Officer, Michael Nall will be presenting at the 26 th Annual ROTH Conference,
Study to be presented at the Society for Neuro-Oncology Third Annual Conference on Brain Metastases, Aug. 19-20 SAN DIEGO --(BUSINESS WIRE)--Aug. 19, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, today announced that new data show the company’s
Case series poster to be presented at the Society for Neuro-Oncology Annual Meeting SAN DIEGO --(BUSINESS WIRE)--Nov. 18, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced the presentation of a multi-institutional case